|MDACC Study No:||2012-0151 (clinicaltrials.gov NCT No: NCT01564784)|
|Title:||An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)|
|Principal Investigator:||Hagop Kantarjian|
|Treatment Agent:||Cytarabine; Fludarabine; G-CSF; Inotuzumab Ozogamicin; Mitoxantrone|
|Study Description:||The goal of this clinical research study is to compare inotuzumab ozogamicin to |
3 other types of chemotherapy treatments when given to patients with relapsed
or refractory ALL. The safety of inotuzumab ozogamicin will also be studied.
Inotuzumab ozogamicin is designed to attach to a protein that is often found in
leukemia cells. This will allow the drug to go inside the cell and may cause
the cancer cells to die.